Novel roles of HIF-PHIs in chronic kidney disease: the link between iron metabolism, kidney function, and FGF23
- 1 July 2021
- journal article
- editorial
- Published by Elsevier BV in Kidney International
- Vol. 100 (1), 14-16
- https://doi.org/10.1016/j.kint.2021.04.030
Abstract
No abstract availableThis publication has 9 references indexed in Scilit:
- Amelioration of chronic kidney disease-associated anemia by vadadustat in mice is not dependent on erythroferroneKidney International, 2021
- Roxadustat for CKD-related Anemia in Non-dialysis PatientsKidney International Reports, 2020
- The HIF-PHI BAY 85-3934 (Molidustat) Improves Anemia and Is Associated With Reduced Levels of Circulating FGF23 in a CKD Mouse ModelJournal of Bone and Mineral Research, 2020
- Regulation of Fibroblast Growth Factor 23 by Iron, EPO, and HIFCurrent Molecular Biology Reports, 2019
- Levels of the erythropoietin-responsive hormone erythroferrone in mice and humans with chronic kidney diseaseHaematologica, 2018
- Prolyl hydroxylase domain inhibitors as a novel therapeutic approach against anemia in chronic kidney diseaseKidney International, 2017
- Identification of erythroferrone as an erythroid regulator of iron metabolismNature Genetics, 2014
- Mechanisms of Anemia in CKDJournal of the American Society of Nephrology, 2012
- The balance of beneficial and deleterious effects of hypoxia-inducible factor activation by prolyl hydroxylase inhibitor in rat remnant kidney depends on the timing of administrationNephrology Dialysis Transplantation, 2012